JP Morgan Chase
NVCR icon

JP Morgan Chase’s NovoCure NVCR Stock Holding History

JP Morgan Chase’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-157,800
Closed -$2.47M – 7625
2024
Q3 		$2.47M Buy
+157,800
New +$2.86M ﹤0.01% 3840
2023
Q1 		– Sell
-77,200
Closed -$5.66M – 7076
2022
Q4 		$5.66M Buy
77,200
+75,500
+4,441% +$5.68M ﹤0.01% 2720
2022
Q3 		$129K Buy
1,700
+400
+31% +$31.2K ﹤0.01% 5170
2022
Q2 		$90K Sell
1,300
-75,200
-98% -$5.66M ﹤0.01% 5462
2022
Q1 		$6.34M Buy
+76,500
New +$5.64M ﹤0.01% 2802
2021
Q4 		– Sell
-1,000
Closed -$116K – 6862
2021
Q3 		$116K Buy
+1,000
New +$151K ﹤0.01% 5496
2021
Q1 		– Sell
-60,000
Closed -$10.4M – 6255
2020
Q4 		$10.4M Buy
+60,000
New +$8.21M ﹤0.01% 2188
2020
Q2 		– Sell
-20,000
Closed -$1.35M – 5595
2020
Q1 		$1.35M Buy
+20,000
New +$1.58M ﹤0.01% 3228

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

JP Morgan Chase's NVCR Position: Q1 2026 in Review

JP Morgan Chase increased its NovoCure (NVCR) stake by 131% in Q1 2026, buying an estimated $6.59M and bringing the position to 930,166 shares worth $9.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2709.

JP Morgan Chase first reported a position in NVCR in Q4 2015 and has held it in 36 quarters since. The position peaked at $31.9M in Q4 2020. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • JP Morgan Chase held 930,166 shares of NovoCure worth $9.64M as of Q1 2026.
  • JP Morgan Chase bought 527,284 NovoCure shares in Q1 2026, an estimated $6.59M.
  • NovoCure made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2709 holding.
  • JP Morgan Chase first reported a position in NovoCure in Q4 2015 and has held it in 36 quarters since.
  • JP Morgan Chase's NovoCure position peaked at $31.9M in Q4 2020.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.